5-MeO-DMT vs 4-AcO-DMT in Australia: Key Differences, Effects, and Legal Status

The question of how 5-MeO-DMT differs from 4-AcO-DMT is one that confuses many Australians exploring psychedelic substances. These two compounds share a tryptamine backbone but produce vastly different experiences. Consequently, understanding their distinctions is crucial for anyone researching these substances in Australia. This guide provides a comprehensive, Australia-oriented comparison of their pharmacology, subjective effects, duration, and legal status.

Understanding the Chemical Relationship

First and foremost, you must understand a critical fact. 5-MeO-DMT and 4-AcO-DMT are completely different compounds despite both belonging to the tryptamine family. They produce fundamentally different experiences and have distinct mechanisms of action.

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a naturally occurring psychedelic found in various plants and the secretions of the Sonoran Desert toad . It is known for its intense, non-visual, and profoundly psychological effects.

4-AcO-DMT (4-acetoxy-N,N-dimethyltryptamine), also known as psilacetin or “synthetic shrooms,” is a semi-synthetic compound. It is the acetylated form of psilocin, the active metabolite of psilocybin mushrooms . Researchers classify it as a prodrug of psilocin, meaning the body converts it into psilocin after ingestion .

Subjective Effects: The Void vs. The Mushroom Realm

The subjective experiences produced by these compounds diverge dramatically.

5-MeO-DMT produces effects that are primarily non-visual and profoundly psychological. One source describes the experience as “a rocket ship into the Void,” noting that “5-MeO-DMT completely dissolves reality as we know it, leaving neither hallucinations nor anyone to watch them” . Users often report ego dissolution, a sense of unity, and encounters with what they interpret as the divine. Visual effects are minimal, often described as a “bright white light” rather than complex imagery.

4-AcO-DMT, by contrast, produces effects that resemble psilocybin mushrooms. Users report colorful visual distortions, enhanced creativity, profound introspection, and feelings of unity and connectedness . One Erowid user described the closed-eye visuals as “really bright… sparkling ‘firework-like’ stuff… along with geometric things” with “phosphorescent, purple, orange, and pink” colors . Another user noted that “the head space reminds me much more of N,N-DMT than shrooms” .

Duration and Onset: A Critical Difference

The duration of effects differs enormously between these compounds.

5-MeO-DMT is an ultra-short-acting psychedelic. When vaporised and inhaled, effects begin almost instantaneously and typically last less than 30 minutes. This brief but overwhelming experience is a defining characteristic of the compound.

4-AcO-DMT, when taken orally, produces effects lasting 3 to 8 hours . The onset is typically 15 to 40 minutes, with a gradual come-up and a gentle comedown . One user reported effects lasting “5 – 8 hours, with a 4 hour peak, and a lingering but gentle and smooth comedown” .

The Australian Legal Status: Both Prohibited

For Australians, understanding the legal status of both compounds is essential.

5-MeO-DMT is a Schedule 9 prohibited substance under the Australian Poisons Standard . The Customs (Prohibited Imports) Regulations explicitly list 5-methoxy-N,N-dimethyltryptamine as a prohibited import. This makes its unlicensed possession, supply, manufacture, or importation illegal across every Australian state and territory.

4-AcO-DMT is also a Schedule 9 prohibited substance in Australia. Australian authorities consider it an analog of psilocin, placing it under the same restrictive classification . The Criminal Code Regulations 2019 explicitly list “4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT)” as a controlled drug .

Consequently, both compounds carry severe legal penalties for possession, supply, or importation in Australia.

Clinical Research Context

Australian clinical research into psychedelics has broadened significantly. The Australia Psychedelic Report 2026 confirms that “Australian clinical and institutional activity broadens across psilocybin, ketamine, DMT-harmala and 5-MeO-DMT work” . The Clinical Psychedelic Lab at Monash University, Australia’s first psychedelic lab, has conducted clinical trials using psilocybin, MDMA, and 5-MeO-DMT for depression, anxiety, and post-traumatic stress .

However, 4-AcO-DMT is not part of any Australian clinical research programme. Its status as a research chemical rather than a naturally occurring compound means it has received less scientific attention.

The Toxicity Profile: A 2026 Study

A 2026 in-silico toxicity study published in Archives of Toxicology assessed key toxicological endpoints for six tryptamines, including 5-MeO-DMT and 4-AcO-DMT .

The study classified all compounds as Cramer Class III (high toxicological concern). Predicted oral LD50 values were in the 100-500 mg/kg range, indicating moderate to high acute toxicity .

Significantly, DMT and 5-MeO-DMT showed the highest predicted hERG inhibition (20 < IC50 < 45 µM), suggesting possible cardiotoxic potential. Psilocybin demonstrated lower risk (IC50 ≈ 760 µM) . The study did not report specific hERG data for 4-AcO-DMT, but noted that most tryptamines were predicted to be non-mutagenic and non-endocrine active .

Harm Reduction Considerations

Given the potency and intensity of 5-MeO-DMT, harm reduction principles are absolutely essential. Research examining community-based harm reduction advice has found that 5-MeO-DMT is not recommended for first-time psychedelic users due to its intensity, mental and physical health risks, and safety concerns .

For 4-AcO-DMT, users report a generally gentler experience than 5-MeO-DMT. Many report less nausea and body load compared to natural psilocybin mushrooms . One user noted “remarkably clear-headed” effects and “no real mindfuck” . However, adverse effects can include anxiety, paranoia, and low mood .

Conclusion

5-MeO-DMT and 4-AcO-DMT are fundamentally different compounds. 5-MeO-DMT produces an ultra-short, intensely psychological, non-visual experience often described as dissolving reality into a void. 4-AcO-DMT produces a psilocybin-like experience lasting several hours, with colorful visuals and a more gentle, introspective character.

In Australia, both compounds remain Schedule 9 prohibited substances with severe penalties for possession, supply, or importation. Neither is available through legal channels outside of approved clinical research.

For Australians interested in these compounds, the responsible path involves understanding their significant differences, respecting the legal framework, and prioritising safety above all else. The wisest course involves remaining informed about clinical research developments while avoiding the legal and health risks associated with unauthorised use.